^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vorbipiprant (CR6086)

    i
    Other names: CR6086
    Associations

    News

    Trials
    Company:
    Rottapharm Biotech
    Drug class:
    PGE4 antagonist
    Related drugs:
    Associations

    News

    Trials
    1m
    Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers (clinicaltrials.gov)
    P1/2, N=107, Active, not recruiting, Rottapharm Biotech | Recruiting --> Active, not recruiting
    Enrollment closed • Mismatch repair • pMMR
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF wild-type • RAS mutation
    |
    balstilimab (AGEN2034) • vorbipiprant (CR6086)
    6ms
    Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers (clinicaltrials.gov)
    P1/2, N=107, Recruiting, Rottapharm Biotech | N=55 --> 107 | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date • Mismatch repair • pMMR
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF wild-type • RAS mutation
    |
    balstilimab (AGEN2034) • vorbipiprant (CR6086)
    over1year
    CR6086/AGEN2034 Combination in Stage IV pMMR - MSS CRC, and Other Metastatic GI Cancers (clinicaltrials.gov)
    P1/2, N=55, Recruiting, Rottapharm Biotech | Active, not recruiting --> Recruiting | N=28 --> 55 | Trial completion date: Dec 2024 --> Sep 2026 | Trial primary completion date: Oct 2023 --> Mar 2025
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Mismatch repair • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    balstilimab (AGEN2034) • vorbipiprant (CR6086)
    over2years
    A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients (clinicaltrials.gov)
    P1/2, N=28, Active, not recruiting, Rottapharm Biotech | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2023 --> Oct 2023
    Enrollment closed • Trial primary completion date • Combination therapy • Mismatch repair • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF wild-type • RAS mutation
    |
    balstilimab (AGEN2034) • vorbipiprant (CR6086)
    almost4years
    A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients (clinicaltrials.gov)
    P1/2, N=27, Recruiting, Rottapharm Biotech
    New P1/2 trial • Combination therapy • Mismatch repair
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF wild-type
    |
    balstilimab (AGEN2034) • vorbipiprant (CR6086)